Clinical Trials Logo

Sarcoma, Ewing clinical trials

View clinical trials related to Sarcoma, Ewing.

Filter by:

NCT ID: NCT05302921 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Start date: February 18, 2022
Phase: Phase 2
Study type: Interventional

The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2 dose (RP2D) in pediatric and young adult patients with relapsed or refractory solid tumors.

NCT ID: NCT05275426 Recruiting - Ewing Sarcoma Clinical Trials

A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor

Start date: March 2, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether LY2880070 combined with the chemotherapy drug gemcitabine is an effective treatment for Ewing sarcoma or Ewing-like sarcoma.

NCT ID: NCT05266196 Enrolling by invitation - Ewing Sarcoma Clinical Trials

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Start date: January 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are still receiving clinical benefit on completed or closed Salarius sponsored studies.

NCT ID: NCT05182164 Recruiting - Osteosarcoma Clinical Trials

Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

PEMBROCABOSARC
Start date: April 25, 2022
Phase: Phase 2
Study type: Interventional

Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.

NCT ID: NCT05116800 Withdrawn - Soft Tissue Sarcoma Clinical Trials

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Start date: March 1, 2022
Phase: Phase 2
Study type: Interventional

This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma. 9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.

NCT ID: NCT05100368 Completed - Sarcoma, Ewing Clinical Trials

The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma

Start date: April 2, 2021
Phase:
Study type: Observational

Extraction of laboratory data from blood tests prior to surgical and chemotherapy and other histological, clinical and instrumental data related to the patient's history from the digitized medical Digitized medical records and analysis of the same. The medical records of 1000 patients from January 1, 2000, until December 31, 2020

NCT ID: NCT05093322 Completed - Lymphoma Clinical Trials

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Start date: November 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of surufatinib administered in combination with gemcitabine in pediatric patients with recurrent or refractory solid tumors or lymphoma. The study will be conducted in 2 parts.

NCT ID: NCT05071209 Active, not recruiting - Clinical trials for Refractory Malignant Solid Neoplasm

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Start date: December 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT05071001 Recruiting - Clinical trials for Adults Treated During Childhood or Adolescence for a Malignant Bone Tumor (Osteosarcoma and Ewing Sarcoma)

Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence

OSE
Start date: March 19, 2021
Phase: N/A
Study type: Interventional

To assess the neurocognitive outcomes in patients treated with chemotherapy for a malignant bone tumor during childhood and adolescence and the factors associated with neurocognitive impairment and/or complaints

NCT ID: NCT05062707 Recruiting - Breast Cancer Clinical Trials

Early Ageing During Therapy in AYA Cancer Patients

Start date: February 10, 2022
Phase:
Study type: Observational

Longitudinal cohort study; measurements before start of systemic therapy and one year later.